Revenue Breakdown
Composition ()
No data
Revenue Streams
HUTCHMED (China) Ltd (HCM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Other venture, accounting for 48.3% of total sales, equivalent to $134.23M. Other significant revenue streams include Immunology- Marketed products and Immunology- R&D. Understanding this composition is critical for investors evaluating how HCM navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, HUTCHMED (China) Ltd maintains a gross margin of 39.65%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1.27%, while the net margin is 164.06%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively HCM converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, HCM competes directly with industry leaders such as INCY and RPRX. With a market capitalization of $2.63B, it holds a significant position in the sector. When comparing efficiency, HCM's gross margin of 39.65% stands against INCY's 92.75% and RPRX's 100.00%. Such benchmarking helps identify whether HUTCHMED (China) Ltd is trading at a premium or discount relative to its financial performance.
